Last reviewed · How we verify
Generic B
Generic B is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and slowing the heart rate and reducing its workload.
Generic B is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and slowing the heart rate and reducing its workload. Used for Hypertension, Angina pectoris, Heart failure.
At a glance
| Generic name | Generic B |
|---|---|
| Also known as | Metoprolol extended-release (ER) |
| Sponsor | University of Florida |
| Drug class | beta-blocker |
| Target | beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Generic B is a non-selective beta-blocker that competes with epinephrine for binding sites on beta-adrenergic receptors in the heart, smooth muscle, and other tissues. This results in decreased heart rate, reduced cardiac output, and decreased peripheral vascular resistance. By reducing the workload on the heart, Generic B can help to alleviate symptoms of angina and reduce the risk of heart attack.
Approved indications
- Hypertension
- Angina pectoris
- Heart failure
Common side effects
- Dizziness
- Fatigue
- Nausea
- Headache
- Cold extremities
Key clinical trials
- Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Hormone Receptor-positive / Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Patients: A Comparative Study
- Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV (NA)
- 4-Aminopyridine to Treat Skin Burns (PHASE2)
- Integrating Hepatological, Nutritional, and Psychological Support as a Multidisciplinary Management to Improve Long-term Clinical Outcomes in MASLD (NA)
- A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) (PHASE1, PHASE2)
- Focal Cerebral Arteriopathy Steroid Trial (PHASE4)
- Miro-randomized Trial for Optimizing a JITAI to Reduce Dietary Lapses in Obesity Treatment (NA)
- A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic B CI brief — competitive landscape report
- Generic B updates RSS · CI watch RSS
- University of Florida portfolio CI